← All trials
NCT03498716
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 2, 2018
- Primary completion
- Jan 15, 2022
- Completion date
- Dec 29, 2024
- First posted
- —
- Last posted
- —
- Enrollment
- 2300
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- RocheLead sponsor
- University of MilanCollaborator
- RocheStudy director
- Alliance Foundation TrialsCollaborator
- Frontier Science and Technology Research Foundation Inc (FS)Collaborator
- Institut Jules BordetCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.